| Pancreatitis Pathology and Treatment | Lifetime | 6 | NL 1 | 99.90 |
| Gallbladder and Bile Duct Disorders | Lifetime | 11 | NL 1 | 99.90 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 18 | NL 1 | 99.90 |
| Gastrointestinal disorders and treatments | Lifetime | 21 | NL 1 | 99.85 |
| Intestinal Malrotation and Obstruction Disorders | Lifetime | 20 | NL 3 | 99.23 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 85 | NL 3 | 99.49 |
| Neuroendocrine Tumor Research Advances | Lifetime | 120 | NL 8 | 99.39 |
| Pediatric Hepatobiliary Diseases and Treatments | Lifetime | 76 | NL 4 | 99.36 |
| Renal cell carcinoma treatment | Lifetime | 151 | NL 6 | 99.15 |
| Appendicitis Diagnosis and Management | Lifetime | 84 | NL 6 | 98.92 |
| Cancer Genomics and Diagnostics | Lifetime | 564 | NL 17 | 98.95 |
| Esophageal and GI Pathology | Lifetime | 580 | NL 41 | 98.06 |
| Biliary and Gastrointestinal Fistulas | Lifetime | 143 | NL 8 | 97.42 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 737 | NL 11 | 97.87 |
| Colorectal Cancer Screening and Detection | Lifetime | 990 | NL 55 | 96.77 |
| Clinical Nutrition and Gastroenterology | Lifetime | 942 | NL 37 | 94.58 |
| Surgical Simulation and Training | Lifetime | 887 | NL 34 | 92.86 |
| Enhanced Recovery After Surgery | Lifetime | 756 | NL 41 | 89.05 |
| Dermatological and COVID-19 studies | Lifetime | 914 | NL 14 | 73.06 |
| Lymphatic Disorders and Treatments | Lifetime | 778 | NL 10 | 57.63 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 2 | NL 1 | 99.93 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 2 | NL 1 | 99.84 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 2 | NL 1 | 99.91 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 7 | NL 1 | 99.42 |
| Cancer Genomics and Diagnostics | 2021-2025 | 44 | NL 1 | 99.55 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 27 | NL 2 | 99.28 |
| Renal cell carcinoma treatment | 2021-2025 | 41 | NL 2 | 99.15 |
| Gastrointestinal disorders and treatments | 2021-2025 | 52 | NL 3 | 97.41 |
| Pediatric Hepatobiliary Diseases and Treatments | 2021-2025 | 59 | NL 5 | 97.06 |
| Esophageal and GI Pathology | 2021-2025 | 142 | NL 21 | 97.53 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 163 | NL 10 | 96.89 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 334 | NL 23 | 97.18 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 305 | NL 4 | 96.62 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 790 | NL 31 | 95.31 |
| Colorectal Cancer Surgical Treatments | 2021-2025 | 765 | NL 55 | 90.40 |
| Biliary and Gastrointestinal Fistulas | 2021-2025 | 132 | NL 6 | 85.24 |
| Surgical Simulation and Training | 2021-2025 | 509 | NL 13 | 86.37 |
| Intestinal Malrotation and Obstruction Disorders | 2021-2025 | 137 | NL 12 | 84.23 |
| Enhanced Recovery After Surgery | 2021-2025 | 352 | NL 20 | 80.38 |
| Appendicitis Diagnosis and Management | 2021-2025 | 806 | NL 46 | 75.30 |
| Anatomy and Medical Technology | 2021-2025 | 609 | NL 19 | 75.11 |
| Health and Medical Research Impacts | 2021-2025 | 790 | NL 16 | 64.79 |
| Lymphatic Disorders and Treatments | 2021-2025 | 207 | NL 2 | 42.58 |
